Authors: Kate Young Ian Chau
Publish Date: 2015/11/30
Volume: 76, Issue: 1, Pages: 13-26
Abstract
The genomic landscape of oesophagogastric OG cancer is highly complex The recent elucidation of some of the pathways involved has suggested a number of novel targets for therapy This therapy is urgently required as with conventional chemotherapy regimens patients with advanced OG cancer still have a median overall survival of under a year This review outlines the rationale for the current treatment of OG cancer with chemotherapy and describes both previously conducted and ongoing clinical trials of novel agents in this area The targets and associated treatments discussed include HER2 EGFR VEGF cMet FGFR2 PI3K mTOR andIGF1 To date only two targeted treatments trastuzumab and ramucirumab have become part of the treatment paradigm for OG cancer partly due to difficulties in defining predictive biomarkers in this disease However there are a number of promising drugs in the pipeline and this article seeks to describe these and other potential novel approaches including targeting DNA repair deficiencies and the immune system
Keywords: